Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Target Price of $20.50 According to Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have received an average rating of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $20.50.

A number of analysts have weighed in on TLX shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday, October 21st. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Finally, Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, September 21st.

Telix Pharmaceuticals Stock Up 0.4%

Shares of TLX stock opened at $9.03 on Friday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $13.11. The firm’s fifty day simple moving average is $11.23 and its 200 day simple moving average is $9.84.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Lazard Asset Management LLC lifted its position in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the period. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Telix Pharmaceuticals during the second quarter valued at approximately $1,731,000. Private Advisor Group LLC increased its position in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period. XY Capital Ltd raised its stake in shares of Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Finally, WoodTrust Financial Corp acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at $186,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.